[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].

作者：Sutong Zhan, Peilin Chen, Tangfeng Lv, Yong Song · 发表于：PubMed · 年份：2026 · DOI：10.3779/j.issn.1009-3419.2026.101.01 · 研究领域：Phagocytosis and Immune Regulation、Liver physiology and pathology、Cancer Mechanisms and Therapy

Although targeted therapy has made significant advances in cancer treatment throughout these years, drug resistance still remains a major obstacle. Plenty of evidence has proved that abnormal expression of receptor tyrosine kinase AXL is associated with targeted therapy resistance and poor clinical outcomes. AXL drives drug resistance through diverse mechanisms, including altering tumor cell phenotypes, orchestrating DNA damage response process, promoting the activation of bypass signals, or interacting with other receptor tyrosine kinases. Preclinical and clinical studies have demonstrated that combined inhibition of AXL and the other target can enhance the efficacy of various targeted therapies and improve outcomes for patients with drug resistance. This review summarizes recent advances in the specific roles of AXL in targeted therapy resistance and AXL-targeted treatment strategies. It further explores the potential clinical value of combinatorial approaches involving AXL inhibition and discusses future directions for its application in developing novel targeted therapies and advancing precision oncology treatment. .